Poster highlighting qualigen therapeutics' pan-ras inhibitor platform presented at american society of clinical oncology (asco) 2023 annual meeting

Preclinical data show potential to overcome resistance to key kras-g12c therapeutic compounds

QLGN Ratings Summary

QLGN Quant Ranking